November 2024 – Page 20

Vertex Pharmaceuticals Surpasses Q3 Expectations, Boosts Annual Revenue Forecast on Strong Cystic Fibrosis Sales

6 months ago talkbio0Tagged Casgevy, Cystic Fibrosis, earnings, full-year, Genetic Therapy, revenue guidance, Suzetrigine, Trikafta sales, vanzacaftor triple, VX-548

Vertex Pharmaceuticals, Q3 2024 earnings, Cystic fibrosis treatments, Trikafta sales, Full-year revenue guidance, Genetic therapies, Vanzacaftor triple, Suzetrigine (VX-548), Casgevy

Historic Settlement: Lacks Family Reaches Agreement with Thermo Fisher Scientific Over Unjust Enrichment from HeLa Cells

6 months ago talkbio0Tagged Biotechnology, Consent, HeLa Cells, Henrietta Lacks, racial injustice, Science, settlement, Thermo Fisher

Henrietta Lacks, HeLa cells, Thermo Fisher Scientific, unjust enrichment, racial injustice, medical ethics, consent, biotechnology, settlement.

Dr. Reddy’s Recalls Over 300,000 Bottles of Thyroid Medication Due to Carcinogen Contamination

6 months ago talkbio0Tagged adulteration, Carcinogens, Dr. Reddy 's, pharmaceutical safety, regulatory, Thyroid preparations, United States Food and Drug Administration

Dr. Reddy’s, thyroid drug recall, carcinogen contamination, pharmaceutical safety, FDA regulations

Novo Nordisk and Ascendis Pharma Collaborate on Groundbreaking Once-Monthly GLP-1 Treatment for Obesity and Type 2 Diabetes

6 months ago talkbio0Tagged Ascendis, Cardiovascular system, GLP-1 receptor, Metabolic Diseases, Nordisk, Obesity, once-monthly, Pharma, Technology, TransCon

Novo Nordisk, Ascendis Pharma, GLP-1 receptor agonist, once-monthly treatment, obesity, type 2 diabetes, metabolic diseases, cardiovascular therapies, TransCon technology.